PRECIPIO, INC. Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Purchases
PRECIPIO, INC. (PRPO) reported Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Purchases of $652.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-27.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPurchases · last filed 2020-03-27
- PRECIPIO, INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, purchases for the quarter ending 2018-12-31 was $199.00K.
- PRECIPIO, INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, purchases for the quarter ending 2018-09-30 was $310.00K.
- PRECIPIO, INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, purchases for the quarter ending 2018-06-30 was $142.00K.
- PRECIPIO, INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, purchases for fiscal 2018 was $652.00K.
| Period end | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Purchases 3 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Purchases 6 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Purchases 9 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Purchases 12 month |
|---|---|---|---|---|
| 2018-12-31 | $199.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $509.00K derived: sum of 2 quarters · filed 2020-03-27 | $651.00K derived: sum of 3 quarters · filed 2020-03-27 | $652.00K 10-K · filed 2020-03-27 |
| 2018-09-30 | $310.00K 10-Q · filed 2019-11-13 | $452.00K derived: sum of 2 quarters · filed 2019-11-13 | $453.00K 10-Q · filed 2019-11-13 | |
| 2018-06-30 | $142.00K 10-Q · filed 2019-08-09 | $142.00K 10-Q · filed 2019-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |